27 Oct 2015 07:00
27 October 2015
Motif Bio plc
("Motif" or the "Company")
Selected to Present at BIO-Europe 2015
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at BIO-Europe, a leading European pharmaceutical-biotechnology conference. The CEO of Motif, Graham Lumsden, will present.
Presentation dates:
The BIO-Europe 2015 conference on November 2 through November 4, 2015 at the International Congress Center (ICM) in Munich, Germany. Motif will be presenting at 16:45 CET on November 3 in Room 2, Level 0.
For further information please contact
Enquiries:
Motif Bio plc Graham Lumsden (Chief Executive Officer) David Huang (Chief Medical Officer) www.motifbio.com
| info@motifbio.com
|
Zeus Capital Limited (NOMINATED ADVISER and BROKER) Phil Walker/Dan Bate Dominic Wilson
| +44 (0) 20 3829 5000 |
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Mark Treharne (Broking) | +44 (0) 20 7382 1100 |
MC Services AG (TRADE PR) Raimund Gabriel Shaun Brown
|
+49 (0) 89 210 2280 +44 (0) 207 148 5998 |
Plumtree Capital Limited (FINANCIAL ADVISOR) Stephen Austin
| +44 (0) 207 183 2493 |
Yellow Jersey PR Limited (FINANCIAL PR) Charles Goodwin Dominic Barretto
| +44 (0) 7747 788 221 |
Notes to Editors:
Motif is a clinical-stage biopharmaceutical company, specialising in the development of novel antibiotics that are designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus). Two Phase III ABSSSI clinical trials are on track to be completed in 2017 and if approved, iclaprim could be ready for commercialization in 2018. The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria. For additional information about Motif please visit www.motifbio.com.